Monitoring of Compliance with Exenatide Prescribing Guidelines in Canada: Drug Utilisation Study of BYETTA in Canada for 2011-2014

09/03/2017
30/03/2024
EU PAS number:
EUPAS17963
Study
Finalised
Study identification

EU PAS number

EUPAS17963

Study ID

19058

Official title and acronym

Monitoring of Compliance with Exenatide Prescribing Guidelines in Canada: Drug Utilisation Study of BYETTA in Canada for 2011-2014

DARWIN EU® study

No

Study countries

Canada

Study description

This was a retrospective cohort study conducted to evaluate adherence to the labelling recommendations for BYETTA use in Canada. Data from the Canadian IMS Brogan’s Longitudinal Patient Data assets (LRx) for 2011-2014 was used.

Study status

Finalised
Research institutions and networks

Institutions

Contact details

Sarah Frise

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

AstraZeneca Canada
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only